Let's talk medical research

In clinical trials, electronic patient-reported outcomes (ePRO) can be used to capture the patient experience in a way that's accessible for patients and creates usable data for your study team.

On March 6th, Antidote’s partners Lupus and Allied Diseases Association and Lupus Research Alliance, along with the Lupus Foundation of America, released the Lupus Patient Voices report.

Today is World Kidney Day. Today and all month (March is National Kidney Month, too), nonprofits and patient advocates will highlight the need for better treatments for and more research around kidney disease, which affects an estimated 31 million people in the United States.

 I can’t count the number of medical conferences I’ve attended over the years. Word to the wise: If you’re a layperson, you’ll probably feel out of place. The discourse is decidedly professional, complete with expert vocabulary and statistical analyses and charts.

March is Multiple Sclerosis (MS) Awareness Month. All month, nonprofit organizations and advocacy groups will highlight promising research into the autoimmune disease.

Interactive Web Response Systems (IWRS) are the technology that clinical trial site managers use to randomize patients and manage drug supplies for a clinical trial. Along with their counterpart from an older generation, Interactive Voice Response Systems (IVRS), the technology falls under the umbrella term Interactive Response Technology (IRT). At least, it used to. Randomization and Trial Supply Management (RTSM) is the new term on the block, and its supporters say that it may help clarify the role the technology plays in clinical trials.

On February 9, you may have heard that Congress renewed funding for the Special Diabetes Program (SDP), a key program that funds diabetes research through the National Institutes of Health (NIH). Our friends at JDRF were heavily involved in advocating for the SDP to be renewed, so we sat down with Cynthia Rice, JDRF’s Senior Vice President of Advocacy and Policy, to learn more.

When Erica Barnes founded Chloe's Fight Rare Disease Foundation along with her husband, Philip, in 2014, she had two goals:

“I have a vision of a world where every single child with a rare disease has a treatment option," said Erica Barnes, founder of Chloe's Fight Rare Disease Foundation.

It's no secret that it's very expensive to bring a new drug to market -- $2.588 billion, to be exact, according to the Tufts Center for the Study of Drug Development. Clinical trial patient recruitment costs account for about one-third of that number.